Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer.

BACKGROUND The aim of this prospective study was to evaluate the value of F-18-fluorodeoxyglucose-positron emission tomography (FDG-PET) for early assessment of chemotherapy response in patients with advanced colorectal cancer. METHODS Dynamic FDG-PET was carried out before and at 2 (n = 50) and 6 months (n = 19) after the start of treatment. Quantitative Patlak analysis [metabolic rate of glucose (MRGlu)] and a simplified method to measure glucose metabolism [standardized uptake value (SUV)] were evaluated. The predictive value of changes in glucose metabolism was assessed with Cox proportional regression analysis. Overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier estimates. RESULTS There was an increase in the rates of death (P = 0.049 for DeltaMRGlu PET1-2; P = 0.017 for DeltaSUV PET1-2; P = 0.032 for DeltaMRGlu PET1-3; P = 0.048 for DeltaSUV PET1-3) and progression (P = 0.026 for DeltaMRGlu PET1-2; P = 0.035 for DeltaSUV PET1-2; P = 0.041 for DeltaMRGlu PET1-3; P = 0.081 for DeltaSUV PET1-3) associated with worse response as assessed by PET on Cox proportional regression analysis. The OS and PFS analysis showed a significant predictive value at broad ranges of DeltaMRGlu and DeltaSUV cut-off levels. CONCLUSION The degree of chemotherapy-induced changes in tumor glucose metabolism is highly predictive for patient outcome. The use of FDG-PET for therapy monitoring seems clinically feasible since simplified methods (SUV) are sufficiently reliable.

[1]  S. Larson,et al.  Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. , 2004, Journal of the American College of Surgeons.

[2]  M. Desco,et al.  18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. , 2004, International journal of radiation oncology, biology, physics.

[3]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  R. Manoliu,et al.  Results of radio frequency ablation of primary and secondary liver tumors: long-term follow-up with computed tomography and positron emission tomography-18F-deoxyfluoroglucose scanning , 2004, Scandinavian journal of gastroenterology. Supplement.

[5]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[6]  Eric J. W. Visser,et al.  Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  S. Goldman,et al.  [F‐18] Fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases , 2003, Journal of surgical oncology.

[8]  L. Strauss,et al.  PET-FDG as predictor of therapy response in patients with colorectal carcinoma. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[9]  H. Biersack,et al.  Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. , 1999, Hybridoma.

[10]  Cesare Guida,et al.  18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  A. Figer,et al.  Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. , 2004, Radiology.

[12]  R. Boellaard,et al.  Measurement of 18F-FDG concentrations in blood samples: comparison of direct calibration and standard solution methods. , 2003, Journal of nuclear medicine technology.

[13]  W. Oyen,et al.  Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Mortelmans,et al.  Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). , 2001, European journal of cancer.

[15]  Cyrill Burger,et al.  Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  T. Hickish,et al.  Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  T. Kato,et al.  Recurrent rectal cancer and scar: differentiation with PET and MR imaging. , 1992, Radiology.

[18]  A. Zwinderman,et al.  Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis. , 2005, Radiology.

[19]  P. Wust,et al.  Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: Is there a benefit in using functional imaging? , 2005, European Radiology.

[20]  V. R. McCready,et al.  The mechanism of accumulation of tumour-localising radiopharmaceuticals , 1998, European Journal of Nuclear Medicine.

[21]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[22]  W. Oyen,et al.  Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[23]  Ying Lu,et al.  Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. , 2002, Radiology.

[24]  W. Oyen,et al.  The impact of fluor‐18‐deoxyglucose‐positron emission tomography in the management of colorectal liver metastases , 2005, Cancer.

[25]  W. Oyen,et al.  Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Johan Nuyts,et al.  Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  G. Bormans,et al.  The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma , 1999, Cancer.

[28]  Peter M. Schlag,et al.  Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  J. Humm,et al.  Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography , 2000, Diseases of the colon and rectum.

[30]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[31]  O. Belohlávek,et al.  The role of FDG-PET/CT in the detection of recurrent colorectal cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  Jan Pruim,et al.  Comparison of image-derived and arterial input functions for estimating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.